Review identifies higher patient exposure for some drugs in chronic inflammation
Academic source · Clinical Pharmacology & Therapeutics / PMC
Source published: · Event / reporting date: 2026-10-29
Site published: 2026-11-05 · Updated: 2026-11-05
This source is linked automatically. Choose a question to get started.
What the paper reports
Based on the article abstract, a review of 20 approved small-molecule medicines for selected chronic inflammatory diseases found more than 25% higher exposure in patients for five medicines, using reported population pharmacokinetic analyses. The authors highlight CYP3A4 and CYP2C19 metabolism. This cross-drug review supports risk assessment, not automatic dose changes for individual patients.
Why this paper is included
Analysis: Dose translation from healthy volunteers may need disease-state assessment; population-model evidence should inform study design rather than stand-alone prescribing decisions.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections